« Back to Record
Citation APA

Verset, G., Borbath, I., Karwal, M., Verslype, C., Van Vlierberghe, H., Kardosh, A., Zagonel, V., Stal, P., Sarker, D., Palmer, D. D., Vogel, A., Edeline, J., Cattan, S., Kudo, M., Cheng, A. L., Ogasawara, S., Daniele, B., Chan, S. L., Knox, J., Qin, S., Siegel, A. A., Chisamore, M., Hatogai, K., Wang, A., Finn, R. R., & Zhu, A. X. (2022). Pembrolizumab Monotherapy for Previously Untreated Advanced Hepatocellular Carcinoma: Data from the Open-Label, Phase II KEYNOTE-224 Trial. Clinical cancer research, 28(12), 2547-2554. doi:10.1158/1078-0432.CCR-21-3807


Permalink

http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/346784

Verset, G., Borbath, I., Karwal, M., Verslype, C., Van Vlierberghe, H., Kardosh, A., Zagonel, V., Stal, P., Sarker, D., Palmer, D. D., Vogel, A., Edeline, J., Cattan, S., Kudo, M., Cheng, A. L., Ogasawara, S., Daniele, B., Chan, S. L., Knox, J., Qin, S., Siegel, A. A., Chisamore, M., Hatogai, K., Wang, A., Finn, R. R., & Zhu, A. X. (2022). Pembrolizumab Monotherapy for Previously Untreated Advanced Hepatocellular Carcinoma: Data from the Open-Label, Phase II KEYNOTE-224 Trial. Clinical cancer research, 28(12), 2547-2554. doi:10.1158/1078-0432.CCR-21-3807